Home > Boards > US Listed > Biotechs > BrainStorm Cell Therapeutics Inc. (BCLI)

Amazing! Matt said he’s getting great results

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Chief-money Member Profile
Member Level 
Followed By 8
Posts 460
Boards Moderated 0
Alias Born 04/09/18
160x600 placeholder
BrainStorm Cell Therapeutics to Present at the 2020 Biotech Showcase and 3rd Annual Neuroscience Innovation Forum at JPM Week... GlobeNewswire Inc. - 1/7/2020 1:00:10 AM
NurOwn® Data Safety Monitoring Board Recommends MS Phase 2 Clinical Trial Continue GlobeNewswire Inc. - 12/19/2019 5:00:10 AM
BrainStorm Issues 2019 Letter to Shareholders GlobeNewswire Inc. - 12/18/2019 5:00:10 AM
BrainStorm Selected as Buzz of BIO 2020 Winner GlobeNewswire Inc. - 12/11/2019 5:00:10 AM
BrainStorm Cell Therapeutics to make scientific presentations at the 30th International Symposium on ALS/MND GlobeNewswire Inc. - 11/26/2019 8:05:45 AM
BrainStorm Announces the Mount Sinai Medical Center as a Progressive MS Phase 2 Clinical Trial Site GlobeNewswire Inc. - 11/25/2019 6:00:10 AM
BrainStorm Cell Therapeutics Announces Publication of NurOwn® ALS Phase 2 Randomized Clinical Trial Data in Neurology GlobeNewswire Inc. - 11/20/2019 7:00:00 AM
BrainStorm Cell Therapeutics Announces Research Grant Award From the National Multiple Sclerosis Society GlobeNewswire Inc. - 11/14/2019 7:00:00 AM
BrainStorm Announces Financial Results for the Third Quarter of 2019 and Provides a Corporate Update GlobeNewswire Inc. - 11/14/2019 6:00:00 AM
BrainStorm Announces Grant of a New Japanese Patent for NurOwn® GlobeNewswire Inc. - 11/13/2019 5:00:00 AM
BrainStorm Cell Therapeutics Announces Ralph Kern MD MHSc to Present at the 7th International Stem Cell Meeting GlobeNewswire Inc. - 11/12/2019 1:00:00 AM
BrainStorm Cell Therapeutics to Announce Third Quarter Financial Results and Provide a Comprehensive Corporate Update GlobeNewswire Inc. - 11/5/2019 6:15:00 AM
NurOwn® Data Safety Monitoring Board Recommends ALS Phase 3 Clinical Trial Continue GlobeNewswire Inc. - 10/28/2019 7:45:05 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 10/25/2019 5:03:11 PM
BrainStorm Cell Therapeutics to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference GlobeNewswire Inc. - 10/25/2019 1:00:05 AM
BrainStorm Cell Therapeutics’ President and CEO to be Featured as Keynote Speaker at Cell Series UK 2019 GlobeNewswire Inc. - 10/24/2019 8:45:58 AM
BrainStorm Cell Therapeutics Presentations at Neuromuscular Drug Development Summit GlobeNewswire Inc. - 10/23/2019 1:00:05 AM
BrainStorm’s NurOwn® Phase 3 ALS Clinical Trial Now Fully Enrolled GlobeNewswire Inc. - 10/11/2019 1:00:00 AM
BrainStorm Announces Notice of US Patent Allowance for NurOwn® Cellular Therapeutic Technology Platform GlobeNewswire Inc. - 10/7/2019 8:04:26 AM
BrainStorm Cell Therapeutics to Present NurOwn® Phase 2 Biomarker Data at North East Amyotrophic Lateral Sclerosis (NEALS) 1... GlobeNewswire Inc. - 10/2/2019 6:45:00 AM
BrainStorm Cell Therapeutics Announces Support for FDA Guidelines on ALS Drug Development GlobeNewswire Inc. - 9/27/2019 4:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/9/2019 8:01:47 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/9/2019 8:01:32 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 9/9/2019 8:01:03 AM
BrainStorm Strengthens Senior Executive Management Team with the Appointment of Preetam Shah, Ph.D., M.B.A., as Chief Financi... GlobeNewswire Inc. - 9/9/2019 1:00:00 AM
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist